Article
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Nov 2014
Chung C H, Lee J W, Slebos R J, Howard J D, Perez J, Kang H, Fertig E J, Considine M, Gilbert J, Murphy B A, Nallur S, Paranjape T, Jordan R C, Garcia J, Burtness B, Forastiere A A, Weidhaas J B
Abstract excerpt
BACKGROUND: A germline mutation in the 3'-untranslated region of KRAS (rs61764370, KRAS-variant: TG/GG) has previously been associated with altered patient outcome and drug resistance/sensitivity in various cancers. We examined the prognostic and predictive significance of this variant in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: We conducted a retrospective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
